HER2 status in ovarian carcinomas: A multicenter GINECO study of 320 patients

PLoS ONE

Volumn 2, Issue 11, 2007, Pages

  Tuefferd, Marianne ^a   Couturier, Jérôme ^b   Penault Llorca, Frédérique ^c   Vincent Salomon, Anne ^b   Broët, Philippe ^a   Guastalla, Jean Paul ^d   Allouache, Djelila ^e   Combe, Martin ^f   Weber, Béatrice ^g   Pujade Lauraine, Eric ^a,h   Camilleri Broët, Sophie ^a,h  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b INSTITUT CURIE   (France)

^c CENTRE JEAN PERRIN   (France)

^d CENTRE LÉON BÉRARD   (France)

^e CENTRE FRANÇOIS BACLESSE   (France)

^f CENTRE HOSPITALIER   (France)

^g CENTRE ALEXIS VAUTRIN   (France)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; PACLITAXEL; PARAFFIN; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ALGORITHM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; OVARIECTOMY; OVARY CARCINOMA; PHARMACOGENETICS; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; GENETICS; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROTO ONCOGENE; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 41149155032     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001138     Document Type: Article

References (43)

1. Ozols RF (2006) Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol 33: S3-11.
2. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235: 177-182.
4. Pritcnard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, et al. (2006) National Cancer Institute of Canada Clinical Trials Group HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354: 2103-2111.
5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
6. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, et al. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648.
7. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac I, et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group, J Clin Oncol 23: 4265-4274.
8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, et al. (2005) Herceptin Adjuvant (HERA) Trial Study Team Trastuzumab after adjuvant chemotherapy in. HER2-positive breast cancer. N Engl J Med 353: 1659-1672.
9. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, et al. (2002) Evaluation of HEP2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens J Clin Oncol 20: 3095-3105.
10. Vincent-Salomon A, MacGrogan G, Couturier J, Arnould L, Denoux Y, et al. (2003) Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology 42: 337-347.
11. Ellis IO, Bartlett J, Dowsett M, Humphreys S, Jasani B, et al. (2004) Best Practice No 176: Updated recommendations for HER2 testing in the UK. J Clin Pathol 57: 233-237.
12. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, et al. (2001) Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 19:2714-2721.
13. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, et al. (2006) HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24: 3032-3038.
14. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, et al. (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25: 118-145.
15. Singleton TP, Perrone T, Oakley G, Nichanis GA, Carson L, et al. (1994) Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage. Cancer 73: 1460-1466.
16. Meden H, Marx D, Rath W, Kron M, Fattahi-Meibodi A, et al. (1994) Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 13: 45-53.
17. Felip E, Del Campo JM, Rubio D, Vera R, del Campo JM, et al. (1995) Overexpression of c-erbB-2 in epithelial ovarian cancer. Prognostic value and relationship with response to chemotherapy. Cancer 75: 2147-2152.
18. Fajac A, Benard J, Lhomme, C, Rey A, Duvillard P, et al. (1995) c-crbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate, analysis. Int J Cancer 64: 146-151.
19. Young SR, Liu WH, Brock JA, Smith ST (1996) ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization. Genes Chromosomes Cancer 16: 130-137.
20. Goff BA, Ries JA, Els LP, Coltrera MD, Gown AM (1998) Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. Gynecol Oncol 70: 378-385.
21. Ferrandina, G, Ranelletti FO, Lauriola I, Fanfani F, Legge F, et al. (2002) Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and HEP2/neu expression in ovarian cancer. Gynecol Oncol 85: 305-310.
22. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR (2003) Evaluation of monoclonal humanized anti-HER2 antibody, tramizumab, in patients with recurrent or refractory ovarian or primmy peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21: 283-290..
23. Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Rock JE, et al. (2003) Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study. Cancer 98: 66-73.
24. Camilleri-Broët S, Hardy-Bessard AC, Le Tourneau A, Paraiso D, Ievrel O, et al. (2004) HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. Ann Oncol 15: 104-112.
25. Clover MG, Kyshtoobayeva A, Burger RA, Yu IR, Fruehauf JP (2004) In vitro chemoresistance and biomarker profiles arc unique for histologic subtypes of epithelial ovarian Cancer. Gynecol Oncol 92: 160-166.
26. Erkinheimo TL, Lassus H, Finne P, van Rees BP, Leminen A, et al. (2004) Elevated cycloaxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma. Clin Cancer Res 10: 538--545.
27. Kupryjanczyk J, Madry R, Plisiecka-Halasa J, Bar J, Kraszewska E, et al. (2004) TP53 status determines clinical significance of ERBB2 expression in ovarian cancer. Br J Cancer 91: 1916-1923.
28. Lassus H, Leminen A, Vayrynen A, et al. (2004) ERBB2 amplification is superior to protein expression status in predisting patient outcome in serous ovarian carcinoma. Gynecol Oncol 92: 31-39.
29. Mano MS, Awada A, Di Leo A, Durbecq V, Paesmans M, et al. (2004) Rates of topoisomerase II-alpha and HER2 gene amplification and expression in epithelial ovarian carcinoma. Gynecol Oncol 92: 887-895.
30. Nielsen JS, Jakobsen, E, Holund B, Bertelsen K, Jakobsen A (2004) Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 14: 1086-1096.
31. Lee CH, Huntsman DG, Cheang MC, Parker RL, Brown L, et al. (2005) Assessment of Her-1, Her-2, and Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol 24: 147-152.
32. Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A, et al. (2005) HEP2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Oncology 68: 154-161.
33. Mayr D, Kanitz V, Amann G, Engel J, Borges A, et al. (2006) HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays. Histopathology 48: 149-156.
34. Press MY, Sauter G, Bernstein L, Villalobos IE, Mirlacher M, et al. (2005) Diagnostic evaluation of HER-2 as a molecular target an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11: 659B-6607.
35. Gouvea AP, Milanezi F, Olson SJ, Leitao D, Schmitt FC, et al. (2006) Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Appl Immunohistochem Mol Morphol. 14: 103-8.
36. Couturier J, Vincent-Salomon A, Nicolas A, Beuzeboc P, Mouret E, et al. (2000) Strong correlation between results of fluorescent in situ hybridization and immumohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol 13: 1238-43.
37. Tokunaga E, Oki E, Nishida K, Koga T, Egashira A, et al. (2006) Trastuzumab and breast cancer developments and current status. Int J Clin Oncol 11: 199-208.
38. BarretC C, Magee H, O'Toole D, Daly S, Jeffers M, et al. (2007) Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry? J Clin Pathol 60: 690-693.
39. Serrano-Olvers. A, Duenas-Gonzalez A, Gallardo-Rincon D, Candelaria M, De la Garza-Salazar J (2006) Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat Rev 32: 180-190.
40. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, et al, (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087-4091.
41. Yamauchi H, Stearns V, Hayes DF (2001) When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19: 2334-2356.
42. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, et al. (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352: 2302-2313.
43. Aigner A, Hsieh SS, Malercyk C, Czubayko F (2000) Reversal of HER2 overexpression renders human ovarian cancer cells highly resistant to taxol. Toxicology 144: 221-228.